@vjhemonc Avatar @vjhemonc VJHemOnc – Video Journal of Hematology & HemOnc

VJHemOnc – Video Journal of Hematology & HemOnc posts on YouTube about university of, italy, in the, interview the most. They currently have [------] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [------] #

Followers Line Chart

CreatorRank: [---------] #

CreatorRank Line Chart

Social Influence

Social category influence countries 36.96% travel destinations 21.74% finance 10.87% technology brands 2.17% celebrities 0.72% musicians 0.72% stocks 0.72% fashion brands 0.72%

Social topic influence university of 34.78%, italy 11.59%, in the 10.87%, interview 9.42%, cell #699, spain 6.52%, stem 5.07%, france 5.07%, nct 4.35%, new york 4.35%

Top accounts mentioned or mentioned by @mskccorg

Top assets mentioned Frontline Ltd. (FRO) Dana Incorporated (DAN)

Top Social Posts

Top posts by engagements in the last [--] hours

"Post-infusion ALCpeak predicts delayed neurotoxicity in patients with myeloma receiving cilta-cel Kenneth Lim MBBS Australian Centre for Blood Diseases Monash University Melbourne Australia discusses the value of post-infusion peak absolute lymphocyte count (ALCpeak) as a marker for assessing the risk of delayed neurotoxicities in patients with multiple myeloma (MM) receiving ciltacabtagene autoleucel (cilta-cel). Dr Lim also mentions an investigation into whether dexamethasone prophylaxis may play a role in reducing the risk of delayed neurotoxicity in this setting. This interview took place"
YouTube Link 2026-02-11T11:53Z 17K followers, [--] engagements

"Performance status outperforms comorbidities as a predictor of survival after BsAb treatment in LBCL Geoffrey Shouse DO PhD City of Hope Comprehensive Cancer Center Duarte CA discusses the predictive value of performance status in patients with large B-cell lymphoma (LBCL) receiving bispecific antibody (BsAb) treatment highlighting that performance status outperforms comorbidity scores as a predictor of survival outcomes in this setting. As baseline comorbidities did not appear to be associated with survival this suggests that comorbidities may not preclude the use of BsAb treatment in"
YouTube Link 2026-02-11T12:11Z 17K followers, [--] engagements

"Adverse events to monitor for following cilta-cel infusion in myeloma: early-onset CRS & IEC-EC In this video Kenneth Lim MBBS Australian Centre for Blood Diseases Monash University Melbourne Australia highlights some adverse events (AEs) that physicians should be aware of when treating patients with multiple myeloma (MM) with ciltacabtagene autoleucel (cilta-cel). Dr Lim notes that cytokine release syndrome (CRS) can often occur earlier post-infusion with cilta-cel than with CAR-T constructs used in lymphoma underscoring the importance of monitoring for early-onset CRS. He also mentions the"
YouTube Link 2026-02-11T16:52Z 17K followers, [--] engagements

"Real-world outcomes of bispecific antibody treatment in patients with double-hit lymphoma In this video Geoffrey Shouse DO PhD City of Hope Comprehensive Cancer Center Duarte CA presents the findings from a real-world evidence study evaluating outcomes of bispecific antibody treatment in patients with double-hit lymphoma a high-risk subgroup of large B-cell lymphoma (LBCL). Double-hit disease was defined as patients with MYC and BCL2 translocations with some patients also harboring BCL6 translocations. This interview took place virtually. These works are owned by Magdalen Medical Publishing"
YouTube Link 2026-02-11T11:23Z 17K followers, [--] engagements

"The largest analysis of real-world outcomes with bispecific antibodies after CAR-T failure in LBCL In this video Megan Melody MD Northwestern University Feinberg School of Medicine Chicago IL discusses the results of the largest retrospective analysis to date examining the real-world outcomes with bispecific antibody treatment following CAR-T failure in patients with large B-cell lymphoma (LBCL). Dr Melody notes that the efficacy of bispecific antibodies is not significantly reduced in patients who have previously received CAR T-cell therapy making them a valuable therapeutic option in this"
YouTube Link 2026-02-11T14:30Z 17K followers, [--] engagements

"The impact of prior transplantation on the durability and efficacy of tisa-cel in pediatric ALL Rakefet Sidlik Muskatel MD PhD Schneider Children's Medical Center of Israel Petah Tikva Israel discusses the impact of prior allogeneic stem cell transplantation (alloSCT) on the durability and efficacy of tisagenlecleucel (tisa-cel) treatment in pediatric patients with acute lymphoblastic leukemia (ALL). She highlights that in a small cohort of patients longer CAR T-cell persistence was observed in those who underwent alloSCT before tisa-cel therapy and suggests two possible explanations for"
YouTube Link 2026-02-13T14:33Z 17K followers, [--] engagements

"An update on the rapidly evolving field of CAR T-cell therapy in autoimmune diseases Raffaella Greco MD PhD San Raffaele Hospital Milan Italy discusses the evolving field of CAR T-cell therapy in autoimmune diseases highlighting encouraging results in conditions such as lupus myositis and systemic sclerosis as well as in neurological autoimmune diseases such as myasthenia gravis and multiple sclerosis. Dr Greco notes that CAR T-cell therapy may also represent a promising approach for the treatment of hematological autoimmune diseases including autoimmune hemolytic anemia immune"
YouTube Link 2026-02-13T13:00Z 17K followers, [--] engagements

"The safety and efficacy of var-cel (ARI-0001) in patients with R/R mantle cell lymphoma Nil Albiol MD Hospital Clnic de Barcelona Barcelona Spain discusses the findings of a study evaluating the safety and efficacy of varnimcabtagene autoleucel (var-cel; ARI-0001) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Dr Albiol notes that the results were encouraging with the main factor influencing overall survival (OS) being whether or not the patient achieved a complete response (CR). This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting held in Palma de"
YouTube Link 2026-02-13T14:45Z 17K followers, [--] engagements

"Fertility management and outcomes in patients undergoing CAR T-cell therapy In this video Giorgio Orofino MD IRCCS San Raffaele Hospital Scientific Institute Milan Italy discusses the findings of a survey conducted on behalf of the Cellular-Therapy and Immunobiology Working Party (CTIWP) of the EBMT to investigate fertility management and outcomes in patients undergoing CAR T-cell therapy. The survey highlighted significant heterogeneity in fertility-related practices between centers and Dr Orofino emphasizes the need for standardized guidelines in this evolving field. The study also reported"
YouTube Link 2026-02-13T14:35Z 17K followers, [--] engagements

"Copanlisib plus nivolumab in Richter's transformation or transformed NHL: Phase I results Geoffrey Shouse DO PhD City of Hope Comprehensive Cancer Center Duarte CA discusses the results of a Phase I trial (NCT03884998) investigating the combination of copanlisib and nivolumab in patients with Richter's transformation (RT) or transformed non-Hodgkin lymphoma (NHL). The combination therapy had a manageable toxicity profile and response rates were promising especially among patients with transformed NHL despite the significant burden of prior therapies. This interview took place virtually. These"
YouTube Link 2026-02-11T16:33Z 17K followers, [--] engagements

"Improving patient selection and referral for CAR T-cell therapy in autoimmune diseases Raffaella Greco MD PhD San Raffaele Hospital Milan Italy discusses the importance of improving patient selection for CAR T-cell therapy in autoimmune disease highlighting the need for clear identification of patients who require this intensive treatment approach. Dr Greco also notes that increased knowledge and awareness among specialists and hematologists will facilitate better patient selection and referral to specialized treatment centers. This interview took place at the EBMT-EHA 8th European CAR T-cell"
YouTube Link 2026-02-13T13:30Z 17K followers, [--] engagements

"Where is the field of CAR-T moving for the treatment of autoimmune diseases In this video Raffaella Greco MD PhD San Raffaele Hospital Milan Italy briefly discusses the future of CAR T-cell therapy for autoimmune diseases anticipating possible approvals for certain indications in the next year. Dr Greco highlights the need for additional clinical trial data and research to confirm the encouraging results observed with CAR-T so far and to expand this therapeutic approach to a broader range of indications. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting held in Palma"
YouTube Link 2026-02-13T13:15Z 17K followers, [--] engagements

"The safety and efficacy of etavopivat in SCD Santosh Saraf MD University of Illinois Hospital Chicago IL briefly discusses the safety and efficacy of etavopivat in sickle cell disease (SCD) highlighting the mechanism of action of this agent and promising activity observed in various studies. This interview took place at the European Hematology Association (EHA) Congress [----] held in Vienna Austria. Speaker: Santosh Saraf Institution: University of Illinois Hospital Event: EHA [----] Format: Interview Subject: Rare Diseases Subject: Sickle Cell Disease Field: Treatment Medicines: Etavopivat"
YouTube Link 2022-06-29T10:56Z 17K followers, [---] engagements

"Advice for community physicians monitoring patients for less common toxicities following CAR-T Megan Melody Dr Northwestern University Feinberg School of Medicine Chicago IL discusses the importance of community physicians monitoring for less common toxicities associated with CAR T-cell therapy such as immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) prolonged cytopenias and profound infections. Dr Melody emphasizes the importance of collaboration between community physicians and CAR-T treating centers to manage these toxicities and improve patient"
YouTube Link 2026-02-10T18:08Z 17K followers, [--] engagements

"LncRNA expression in IgM MGUS: a potential malignant driver for WM Waldenstrms macroglobulinemia (WM) is preceded by an IgM monoclonal gammopathy of undetermined significance (MGUS) and our understanding of the underlying pathobiology of these conditions is still evolving. Stephen Ansell MD PhD Mayo Clinic Rochester MN discusses the long non-coding (lnc)RNA expression profile in patients with WM and MGUS. Several known oncogenes were found to be in proximity of overexpressed lncRNAs in WM compared to IgM MGUS which suggests that this could be a potential mechanism driving the transformation"
YouTube Link 2020-01-24T16:08Z 17K followers, [----] engagements

"Updated analysis of the MAIA trial: long-term safety and efficacy data Supratik Basu MBBS MRCP FRCPath FRCP The Royal Wolverhampton Hospital NHS Trust Wolverhampton UK shares an update on the Phase III MAIA trial (NCT02252172) which is evaluating the safety and efficacy of adding daratumumab to lenalidomide and dexamethasone in patients with transplant-ineligible multiple myeloma. Long-term follow-up data demonstrate that there is a significant progression-free survival and overall survival (PFS; OS) advantage in patients receiving the daratumumab-containing regimen confirming the well"
YouTube Link 2023-06-01T11:42Z 17K followers, [---] engagements

"Comparing consolidation options in CNS lymphoma: autoSCT & reduced-dose whole-brain radiation Kathryn Tringale MD UC San Diego Health San Diego CA discusses the treatment paradigm for primary CNS lymphoma highlighting the importance of consolidation regimens after induction with high-dose methotrexate-containing regimens. Dr Tringale notes that autologous stem cell transplantation (autoSCT) and reduced-dose whole-brain radiation therapy have shown durable control with the latter potentially preferred to non-myeloablative chemotherapy due to its lower toxicity profile. This interview took"
YouTube Link 2025-06-25T07:58Z 17K followers, [---] engagements

"Neurological symptoms indicative of primary CNS lymphoma: advice for community physicians Lakshmi Nayak MD Dana-Farber Cancer Institute Boston MA shares insights into the neurological symptoms associated with primary CNS lymphoma highlighting that confusion cognitive deficits and memory disorders are common. Dr Nayak notes that these symptoms progress rapidly over weeks distinguishing them from the insidious course of memory disorders and emphasizes the importance of monitoring the timeline and trajectory of symptoms. This interview took place at the 13th Annual Meeting of the Society of"
YouTube Link 2025-09-10T12:41Z 17K followers, [---] engagements

"5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera Srdan Verstovek MD PhD Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX discusses the long-term follow-up results of a phase III trial (NCT01949805) and extension study of ropeginterferon alfa-2b compared to standard cytoreductive therapy in polycythemia vera (PV). Ropeginterferon alfa-2b is a novel long-acting interferon with a pharmacokinetic profile that offers improved tolerability which can selectively target malignant clones. A high rate of sustained molecular"
YouTube Link 2020-12-06T14:30Z 17K followers, [----] engagements

"Register for the hybrid EBMT-EHA 8th European CAR T-cell meeting: a message from the chair In this video Annalisa Ruggeri MD IRCCS San Raffaele Hospital Scientific Institute Milan Italy encourages viewers to register for the EBMT-EHA 8th European CAR T-cell meeting taking place in Palma de Mallorca Spain and online. This hybrid event will bring together leading experts in CAR-T and cellular therapies to share ideas and updates in the field. This interview took place virtually. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around"
YouTube Link 2026-02-05T13:02Z 17K followers, [--] engagements

"Top ASH [----] updates in AML: redefining frontline therapy menin inhibition & more This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH [----] spanning frontline therapy molecularly targeted approaches venetoclax-based combinations and emerging immunotherapies. Amir Fathi MD MPH Massachusetts General Hospital Boston MA discusses the Phase II PARADIGM study (NCT04801797) comparing azacitidine plus venetoclax with intensive chemotherapy alongside updated KOMET-007 trial (NCT05735184) results of ziftomenib plus azacitidine and venetoclax in NPM1-mutated or"
YouTube Link 2026-02-03T08:57Z 17K followers, [---] engagements

"A real-world analysis of the outcomes of patients with PNH treated with iptacopan Iptacopan was the first oral complement inhibitor approved by the US Food and Drug Administration (FDA) for the management of patients with paroxysmal nocturnal hemoglobinuria (PNH). Carmelo Gurnari MD Cleveland Clinic Cleveland OH outlines the findings of a real-world analysis of data from patients treated with this agent either as first-line treatment or after prior intravenous therapy. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen"
YouTube Link 2025-12-10T10:11Z 17K followers, [--] engagements

"Harnessing the benefits of CD34+ cells collected for double HSCT in patients with multiple myeloma Sergio Giralt MD Memorial Sloan Kettering Cancer Center New York NY comments on the potential uses for CD34+ cells collected for double hematopoietic stem cell transplantation (HSCT) in patients with multiple myeloma. Whilst modern apheresis techniques enable the collection of enough cells for double transplants full usage of these cells rarely occurs. Additional uses for the apheresis products include salvage transplantation especially in patients with long-term thrombocytopenia. This interview"
YouTube Link 2022-11-16T12:01Z 17K followers, [---] engagements

"Outcomes of patients with B-ALL with concomitant Ph+ and CRLF2 rearrangements Nitin Jain MD University of Texas MD Anderson Cancer Center Houston TX outlines results from a retrospective analysis of patients with B-cell acute lymphoblastic leukemia (B-ALL) with concomitant BCR-ABL1 and CRLF2 rearrangements. The analysis found that treating this subgroup of patients with immunotherapy plus tyrosine kinase inhibitors (TKI) cleared the Ph+clone but the CRLF2-rearranged clone still persisted which likely causes relapse of the disease. Overall patients who harbor concomitant Ph+ and CRLF2"
YouTube Link 2023-01-03T13:17Z 17K followers, [----] engagements

"Streamlining CAR T-cell therapy: a multidisciplinary screening tool to improve brain-to-vein time Megan Melody MD Northwestern University Feinberg School of Medicine Chicago IL discusses the development and validation of a multidisciplinary screening tool to improve brain-to-vein (B2V) time and streamline CAR T-cell therapy in hematological malignancies. The questionnaire aims to evaluate potential barriers to CAR T-cell therapy and ideally replace standard institutional evaluations for selected patients enabling expedited apheresis and reducing B2V time. This interview took place virtually."
YouTube Link 2026-02-10T15:03Z 17K followers, [--] engagements

"Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis Harinder Gill MBBS PDipID MD MRCP FRCPath FHKCP FHKAM The University of Hong Kong Hong Kong China shares some insights into the P1101MF study (NCT04988815) which is evaluating the safety and efficacy of ropeginterferon alfa-2b in patients with pre-fibrotic myelofibrosis (MF). Dr Gill comments on the rate of hematologic response observed and further highlights the promise of this agent for the treatment of MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans LA."
YouTube Link 2023-02-03T15:27Z 17K followers, [----] engagements

"ASH [----] highlights in AL amyloidosis: risk stratification bispecific antibodies CAR-T & MRD This VJHemOnc podcast highlights key AL amyloidosis updates from ASH [----] spanning risk stratification optimisation of frontline therapy emerging immunotherapies and MRD assessment. Jahanzaib Khwaja MD FRCPath University College London Hospitals NHS Foundation Trust London UK discusses a newly validated staging system defining ultra-high-risk AL amyloidosis in the era of daratumumab-based therapy. Vaishali Sanchorawala MD Boston University School of Medicine Boston MA presents Phase II AQUARIUS trial"
YouTube Link 2026-02-06T14:23Z 17K followers, [--] engagements

"Improving the specificity of molecular MRD detection Measurable residual disease (MRD) is becoming increasingly important in the field of leukemia research as emphasized here by Christopher Hourigan DM DPhil FACP FRCP of the National Heart Lung and Blood Institute National Institutes of Health Bethesda MD. Dr Hourigan discusses the challenges of specificity and false positives when using next-generation sequencing for MRD detection and the methodologies that are working on overcoming these issues. This interview took place at the International Symposium on Acute Leukemias (ISAL) [----] held in"
YouTube Link 2019-06-26T16:41Z 17K followers, [--] engagements

"Ropeginterferon alpha-2b as an effective treatment against PV Polycythemia vera (PV) a disorder which results in the over-production of red blood cells is commonly treated with the drug hydroxyurea. Jean-Jacques Kiladjian MD PhD from Saint-Louis Hospital and Paris Diderot University Paris France talks about the results of PROUD-PV (NCT01949805) the first randomized trial to compare the efficacy of ropeginterferon alpha-2b against hydroxyurea as a first-line treatment against PV. He also talks us through a second study which focused on examining the effect of ropeginterferon and hydroxyurea"
YouTube Link 2017-07-26T14:38Z 17K followers, [----] engagements

"Anchored indirect treatment comparison of pegcetacoplan and iptacopan for PNH In this video Jeff Szer MBBS FRACP Peter MacCallum Cancer Centre Melbourne Australia briefly discusses an anchored indirect treatment comparison of pegcetacoplan and iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had a suboptimal response to prior C5 inhibitor treatment. This analysis found comparable response rates between the two proximal complement inhibitors. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris France. These works are owned by"
YouTube Link 2025-05-20T09:16Z 17K followers, [---] engagements

"Predictive factors for successful treatment-free remission in CML Fadi Haddad MD The University of Texas MD Anderson Cancer Center Houston TX discusses a pooled analysis evaluating predictive factors for successful treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML). The analysis found sustained deep molecular remission particularly of long duration as the strongest predictor of durable TFR. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by"
YouTube Link 2026-01-21T12:53Z 17K followers, [--] engagements

"Rethinking surveillance postCAR-T in LBCL due to the low incidence of late-onset toxicities Megan Melody MD Northwestern University Feinberg School of Medicine Chicago IL presents the findings of the largest real-world study examining the incidence of late-onset cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) associated with FDA-approved anti-CD19 CAR T-cell therapies in large B-cell lymphoma (LBCL). Dr Melody highlights that the risk of late-onset CRS or ICANS (occurring more than [--] days post-infusion) was low across all constructs"
YouTube Link 2026-02-10T16:20Z 17K followers, [--] engagements

"Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations Jennifer Marvin-Peek MD The University of Texas MD Anderson Cancer Center Houston TX shares the practice-changing highlights in myelodysplastic syndromes (MDS) from ASH [----]. Dr Marvin-Peek mentions the VERONA trial (NCT04401748) as well as studies investigating triplet regimens. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All"
YouTube Link 2026-01-07T13:27Z 17K followers, [--] engagements

"The real-world outcomes of patients with functional high-risk myeloma receiving cilta-cel In this video Kenneth Lim MBBS Australian Centre for Blood Diseases Monash University Melbourne Australia briefly discusses the real-world outcomes of patients with functional high-risk multiple myeloma receiving ciltacabtagene autoleucel (cilta-cel) highlighting that functional high-risk status does not appear to be an independent poor prognostic factor. This interview took place virtually. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around"
YouTube Link 2026-02-11T10:29Z 17K followers, [--] engagements

"Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma In this video Bruno Paiva PhD University of Navarra Pamplona Spain discusses the importance of combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients with multiple myeloma (MM). This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved."
YouTube Link 2025-12-07T16:01Z 17K followers, [--] engagements

"ATG-based immunosuppressive therapy in elderly patients with aplastic anemia Jayastu Senapati MBBS MD The University of Texas MD Anderson Cancer Center Houston TX shares the results of a study evaluating the outcomes of elderly patients with aplastic anemia treated with anti-thymocyte globulin (ATG)-based immunosuppressive therapy. There were no significant differences in response rates (RR) and relapse-free survival (RFS) between older and younger patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans LA. These works are owned by Magdalen"
YouTube Link 2023-01-19T14:16Z 17K followers, [----] engagements

"The role of Epstein-Barr virus in Hodgkin lymphoma pathophysiology Carlos Almeida Ramos MD PhD Baylor College of Medicine Houston TX comments on the association between Epstein-Barr virus (EBV) and Hodgkin lymphoma (HL) explaining how the virus can transform B-cells into tumor cells. Prof. Almeida Ramos also refers to the recently developed CD30-targeting CAR-modified EBV-specific T-cells (CD30.CAR EBVSTs) which may benefit patients with HL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML) held in Lugano Switzerland. These works are owned by Magdalen"
YouTube Link 2023-07-24T14:15Z 17K followers, [----] engagements

"The importance of optimizing treatment of B-ALL at induction Rachel Rau MD of Baylor College of Medicine Houston TX suggests how treatment can be optimized at induction to achieve the best possible outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL) and explains the importance of optimizing treatment early. Dr Rau also explains that patients in the relapsed/refractory setting who don't respond to chemotherapy may benefit from an earlier introduction of bispecific T-cell engagers (BiTEs) such as blinatumomab. This interview took place during the ninth annual meeting of the"
YouTube Link 2021-09-28T12:00Z 17K followers, [---] engagements

"The changing role of alloSCT in DLBCL in the era of novel agents Matthew Ulrickson MD Banner MD Anderson Cancer Center Gilbert AZ briefly discusses the changing role of allogeneic stem cell transplantation (alloSCT) in diffuse large B-cell lymphoma (DLBCL) in the era of novel agents. Dr Ulrickson highlights the role of alloSCT in younger patients who are eligible for this approach and further comments on the need to improve outcomes with novel CAR products and combination strategies. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML) held in Lugano"
YouTube Link 2023-07-31T12:21Z 16.4K followers, [--] engagements

"Extended follow-up from a Phase I/II study of golcadomide rituximab in patients with R/R DLBCL Marc Hoffman MD University of Kansas Medical Center Kansas City KS discusses extended follow-up results from a Phase I/II study (NCT03930953) of golcadomide rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Hoffman notes that the combination was well tolerated and resulted in durable and sustained responses. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing"
YouTube Link 2025-12-16T14:44Z 16.7K followers, [--] engagements

"Daratumumab vs isatuximab in the treatment of multiple myeloma Saad Usmani MD MBA FACP Memorial Sloan Kettering Cancer Center New York NY compares and contrasts the use of daratumumab and isatuximab in the treatment of multiple myeloma. Dr Usmani explains that whilst the efficacy of these agents is similar they have different dosing schedules and routes of administration. In addition data has shown that these two agents should not be used one after the other. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles CA. These works are owned by"
YouTube Link 2022-09-29T14:51Z 16.8K followers, [----] engagements

"CAR T across hematological malignancies: trials to watch Axicabtagene ciloleucel an anti-CD19 CAR T-cell product has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video recorded at the [----] Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston TX John Rossi MS from Kite Pharma Inc. Santa Monica CA highlights clinical trials in the ZUMA series which are targeting a variety of B-cell malignancies and leukemias with axicabtagene ciloleucel. He also discusses KITE [---] an anti-BCMA CAR T product which is being tested at Phase [--] (NCT03318861) in"
YouTube Link 2018-09-19T16:17Z 16.8K followers, [---] engagements

"Evaluating the impact of tisa-cel in NHL Meryl D. Colton MD University of Colorado Denver CO provides an overview of the effects tisagenlecleucel (tisa-cel) a recently approved chimeric antigen receptor (CAR) T-cell therapy has on the non-Hodgkin lymphoma (NHL) treatment landscape. Tisa-cel has enabled durable responses in heavily pre-treated patients who have received 3-4 prior lines of therapy. Current trials are assessing whether the CAR T-cell therapy can be administered in earlier lines of therapy before autologous stem cell transplantation. This interview took place at the American"
YouTube Link 2022-06-13T11:28Z 16.8K followers, [--] engagements

"Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges Jess San Miguel MD PhD University of Navarra Pamplona Spain discusses challenges in treating patients with multiple myeloma who progress on lenalidomide emphasizing that patients may also become refractory to daratumumab. Prof. San Miguel highlights the need for new therapies and tailored treatment approaches to overcome this challenge. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting held in Rio de Janeiro Brazil. These works are owned by Magdalen Medical"
YouTube Link 2024-10-17T14:44Z 16.8K followers, [---] engagements

"QoL benefits of jaktinib for myelofibrosis patients Jie Jin MD PhD Zhejiang Medical University Hangzhou China discussess the benefits of jaktinib treatment for patients with myelofibrosis higlighting improvements in quality of life (QoL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021"
YouTube Link 2021-06-11T07:00Z 16.8K followers, [--] engagements

"What is considered an "optimal" response when treating a patient with myeloma with CAR-T In this video Doris Hansen MD Moffitt Cancer Center Tampa FL briefly discusses what could be considered an "optimal" response to CAR T-cell therapy in patients with multiple myeloma (MM). Dr Hansen notes that the ideal outcome is a measurable residual disease (MRD)-negative complete remission (CR). However she states that a partial response (PR) or better is also desirable particularly in later lines of treatment. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma"
YouTube Link 2025-11-03T08:58Z 16.4K followers, [--] engagements

"Ruxolitinib combinations in patients with myelofibrosis Jean-Jacques Kiladjian MD PhD Saint-Louis Hospital & Paris Diderot University Paris France suggests that combining ruxolitinib a commonly used JAK inhibitor with drugs that target other pathways involved in disease progression is an effective way to manage difficult-to-treat patients with myelofibrosis (MF). Two promising combinations include pelabresib and navitoclax which have shown clinical responses and improvements in bone marrow fibrosis and JAK2 allele burden in early-phase trials. Large Phase III randomized trials are currently"
YouTube Link 2023-05-17T08:16Z 16.8K followers, [---] engagements

"Social determinants of health & their impact on patients with hematological malignancies Jorge Cortes MD Augusta University Augusta GA discusses a recently published review evaluating the impact of social determinants of health (SDH) on the survival of patients with hematological malignancies. Dr Cortes explains that SDH play an integral role in cancer survival and concludes by highlighting the importance of collecting reporting and standardizing SDH data. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston TX. These"
YouTube Link 2023-10-09T10:39Z 16.8K followers, [--] engagements

"Zella 201: alvocidib-based regimens in MCL-1 dependent high-risk AML Joshua Zeidner MD UNC Lineberger Comprehensive Cancer Center Chapel Hill NC discusses the findings of the Zella [---] trial (NCT02520011) of alvocidib followed by cytarabine and mitoxantrone (ACM) in high-risk acute myeloid leukemia (AML) patients with MCL-1 dependence. Alvocidib is a CDK-9 inhibitor that represses RNApol II-mediated transcription of key leukemia survival genes including the anti-apoptotic MCL-1. Previous clinical trials of ACM showed a correlation between efficacy and MCL-1 dependence so Zella [---] was"
YouTube Link 2020-12-05T23:30Z 16.7K followers, [--] engagements

"Updates and correlative results from the MANIFEST-2 trial Raajit Rampal MD PhD Memorial Sloan Kettering Cancer Center New York NY shares an update on the MANIFEST-2 trial (NCT04603495) investigating pelabresib plus ruxolitinib combination therapy versus ruxolitinib monotherapy in patients with JAK inhibitor-naive myelofibrosis (MF). The combination therapy led to a significantly greater decrease in spleen volume and a numerically greater decrease in total symptom score (TSS). Additionally the combination reduced inflammatory cytokines fibrosis and megakaryocyte clustering. This interview took"
YouTube Link 2024-06-15T10:30Z 16.5K followers, [--] engagements

"Time to third-line treatment after BR +/- acalabrutinib in previously untreated MCL: ECHO analysis Michael Wang MD The University of Texas MD Anderson Cancer Center Houston TX discusses an analysis of the ECHO trial (NCT02972840) investigating time to third-line treatment after bendamustine-rituximab (BR) with or without acalabrutinib in patients with previously untreated mantle cell lymphoma (MCL). Prof. Wang highlights that the analysis shows concurrent therapy with BR and acalabrutinib is superior to sequential therapy. This interview took place at the 67th ASH Annual Meeting and"
YouTube Link 2026-01-07T13:54Z 16.8K followers, [--] engagements

"New algorithm for second-line DLBCL: the role of CAR-T therapy Jason Westin MD FACP The University of Texas MD Anderson Cancer Center Houston TX talks on a new algorithm for the second-line treatment of patients with diffuse large B-cell lymphoma (DLBCL) highlighting the role of CAR-T therapy based on findings from recent clinical trials. Dr Westin comments on the superiority of axicabtagene ciloleucel (axi-cel) over the previous standard of care (SOC) of chemotherapy followed by a stem cell transplant (SCT) adding that the latter approach is preferred if patients experience relapse more than"
YouTube Link 2023-09-15T10:56Z 16.8K followers, [---] engagements

"Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial Jennifer Marvin-Peek MD The University of Texas MD Anderson Cancer Center Houston TX discusses a Phase II trial (NCT07032727) investigating olutasidenib combined with co-targeted therapy in relapsed/refractory (R/R) IDH1-mutated myeloid malignancies harboring activated signaling pathway mutations. This trial aims to target the resistance mechanisms to improve outcomes for these patients. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned"
YouTube Link 2026-01-07T13:18Z 16.8K followers, [--] engagements

"Liquid biopsy in lymphoid malignancies: from genomics to MRD monitoring In this video Gianluca Gaidano MD PhD University of Eastern Piedmont Vercelli Italy shares insights into the value of using liquid biopsy to study lymphoid malignancies and tumors highlighting its ability to provide a comprehensive view of the tumor and monitor its evolution over time. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the"
YouTube Link 2025-09-22T17:24Z 16.4K followers, [--] engagements

"Guidance for treating patients with CLL who have relapsed after initial therapy Marc Hoffman MD University of Kansas Medical Center Kansas City KS gives guidance for treating patients with chronic lymphocytic leukemia (CLL) who have relapsed after initial therapy. Dr Hoffman describes several clinical scenerios and his approach to treatment which is dependent on how the patient has relapsed and which treatment they received. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected"
YouTube Link 2026-01-16T15:40Z 16.9K followers, [--] engagements

"Pembrolizumab and pralatrexate for R/R peripheral T-cell lymphomas In this video Christina Poh MD City of Hope Duarte CA discusses the results of a study (NCT03598998) investigating the combination of pembrolizumab and pralatrexate for relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). The regimen was not well tolerated with an unacceptable rate of dose-limiting toxicities (DLTs) and yielded a lower overall response rate (ORR) compared to historical data for pralatrexate monotherapy. Dr Poh highlights that the study was prematurely discontinued due to these findings suggesting that"
YouTube Link 2026-01-14T16:43Z 16.9K followers, [--] engagements

"The Cassiopeia trial - assessing daratumumab in the context of stem cell transplantation Philippe Moreau MD from the University Hospital of Nantes Nantes France gives an overview of the Cassiopeia trial on daratumumab in transplant eligible multiple myeloma (MM) patients. The trial compares bortezomib thalidomide dexamethasone (VTD) followed by stem cell transplantation followed by two cycles of consolidation therapy with VTD with or without daratumumab (NCT02541383). The primary endpoint is stringent complete remission (CR). Within the same study there is a second randomization with"
YouTube Link 2016-05-27T10:46Z 16.8K followers, [----] engagements

"Comparison of infectious complications in patients with R/R LBCL receiving CAR-T versus bispecifics Gloria Iacoboni MD PhD Vall dHebron Institute of Oncology Barcelona Spain discusses the findings of a retrospective multicenter study comparing infectious complications in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CAR T-cell therapy versus bispecific antibodies. Dr Iacoboni highlights that the incidence of infections was similar between groups with corticosteroid treatment being the most significant risk factor for infection. This interview took place at the"
YouTube Link 2025-12-08T18:01Z 16.6K followers, [--] engagements

"Design and results of pacritinib for myelofibrosis trial (PERSIST-1) Dr Jean-Jacques Kiladjian at the [----] American Society of Clinical Oncology (ASCO) describes the design and recent results of the PERSIST- [--] trial of pacritinib for patients with myelofibrosis with specific focus on the impact on thrombocytopenia low-platelet count and transfusion independence"
YouTube Link 2015-06-11T15:42Z 16.8K followers, [--] engagements

"Using MRD to understand the response to autoSCT in patients with multiple myeloma Susan Bal MD MBBS University of Alabama at Birmingham Birmingham AL discusses the use of measurable residual disease (MRD) prior to and following autologous stem cell transplantation (autoSCT) to understand and quantify the depth of response with this intervention in patients with multiple myeloma (MM). Dr Bal highlights that patients with high-risk cytogenetics appear to derive the greatest benefit from autoSCT and comments on whether receiving CD38 monoclonal antibodies or melphalan in induction affects the"
YouTube Link 2024-01-16T17:36Z 16.8K followers, [---] engagements

"Next steps for advancing the molecular stratification of CLL Anna Schuh MD PhD from the University of Oxford Oxford UK disucsses the next steps for advancing the molecular stratification and treatment of chronic lymphocytic leukemia (CLL). Dr Schuh discusses the Genomics England project which will look at the whole genome data and willl allow researchers to discover more clinically relevant mutations. This will further allow for a better stratification of patients according to Dr Schuh. Recorded at the [----] Annual Meeting of the British Society of Haematology (BSH) and International Society"
YouTube Link 2016-06-21T09:50Z 16.8K followers, [---] engagements

"Key multiple myeloma breakthroughs at ASH [----] In this interview Mohamad Mohty MD PhD Saint-Antoine Hospital Paris France provides insight into some of the key multiple myeloma (MM) breakthroughs at the ASH [----] meeting highlighting the promising early results with in vivo CAR T-cells and mentioning the Phase III MajesTEC-3 trial (NCT05083169) which may lead to the use of anti-BCMA bispecific antibodies in earlier lines of therapy. Prof. Mohty also touches on the importance of measurable residual disease (MRD) assessment combination therapies quality-of-life studies and novel innovations."
YouTube Link 2026-01-07T13:10Z 16.8K followers, [--] engagements

"XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF John Mascarenhas MD Icahn School of Medicine at Mount Sinai New York NY discusses the XPORT-MF-034 study (NCT04562389) which is investigating combination therapy with the XPO-1 inhibitor selinexor and ruxolitinib for JAK-inhibitor-nave myelofibrosis (MF). Selinexor affects multiple pathways relevant to the pathophysiology of MF and early data highlight its efficacy when administered with low-dose ruxolitinib. This interview took place at the 65th ASH Annual Meeting and Exposition held in San Diego CA. These works are owned by"
YouTube Link 2024-02-29T14:02Z 16.8K followers, [---] engagements

"Novel agents in development for the treatment of CML Simona Soverini PhD University of Bologna Bologna Italy comments on promising new molecules in development for the treatment of chronic myeloid leukemia (CML). She highlights two agents currently in Phase I trial which have the potential to expand the treatment options for patients with CML. This interview took place at the 66th ASH Annual Meeting and Exposition held in San Diego CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved"
YouTube Link 2025-01-27T14:40Z 16.6K followers, [--] engagements

"Treating GvHD with MaaT013 a fecal microbiotherapy Florent Malard MD PhD Saint Antoine Hospital Paris France discusses the clinical outcomes from the single-arm phase IIa HERACLES study (NCT03359980) and an expanded access program (EAP) which assessed MaaT013 an allogenic fecal microbiotherapy in patients with steroid refractory intestinal acute graft-versus-host disease (aGvHD). [--] and [--] patients from the HERACLES study and EAP respectively were treated with MaaT013 and clinical benefit was reported in both cohorts in terms of GI-overall response rate (ORR) [--] days after administration and"
YouTube Link 2021-12-11T19:45Z 16.8K followers, [--] engagements

"Phase I study of ABBV-383 a BCMACD3 bispecific antibody in R/R myeloma Ravi Vij MD MBA Washington University Medical School St. Louis MO briefly comments on the results of a Phase I study evaluating ABBV-383 a BCMA CD3 bispecific antibody in patients with relapsed/refractory (R/R) multiple myeloma (NCT03933735). Prof. Vij explains that this agent eliminates the need for step-up dosing therefore reducing the length of hospitalization. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans LA. These works are owned by Magdalen Medical Publishing (MMP)"
YouTube Link 2023-01-24T16:17Z 16.4K followers, [---] engagements

"Olutasidenib alone or in combination with azacitidine in patients with IDH1-mutated MDS Jorge Cortes MD Georgia Cancer Center Augusta University Augusta GA comments on the safety and efficacy of olutasidenib alone or in combination with azacitidine in patients with IDH1-mutated myelodysplastic syndromes (MDS) particularly in those with relapsed/refractory (R/R) disease. Dr Cortes highlights high response rates with mostly complete responses and notes that the responses are remarkably durable. This confirms the value of olutasidenib as an alternative treatment option for these patients. This"
YouTube Link 2025-01-07T17:34Z 17K followers, [--] engagements

"Insights into a Phase II study evaluating ANX005 in wAIHA In this video Ulrich Jger MD Medical University of Vienna Vienna Austria shares some insights into a Phase II study evaluating ANX005 a novel complement antibody for the treatment of warm autoimmune hemolytic anemia (wAIHA). This interview took place at the European Hematology Association (EHA) Congress [----] held in Vienna Austria"
YouTube Link 2022-07-21T16:59Z 16.8K followers, [---] engagements

"Managing sickle cell disease in pregnancy: utilizing prophylactic transfusions in this setting Sheinei Alan MD PhD Inova Schar Cancer Institute Fairfax VA discusses the management of sickle cell disease (SCD) in pregnancy highlighting the importance of a proactive transfusion therapy approach to improve hemoglobin levels and reduce the risk of complications. Dr Alan notes that her approach involves either simple or exchange transfusions depending on patient preference prior pregnancy experience and disease phenotype. This interview took place virtually. These works are owned by Magdalen"
YouTube Link 2025-11-06T13:34Z 16.5K followers, [--] engagements

"ZUMA-5: high ORR and CR for R/R iNHL with axi-cel David Maloney MD PhD Fred Hutchinson Cancer Research Center Seattle WA gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel) an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) including follicular lymphoma and marginal zone lymphoma (MZL). Axi-cel has demonstrated a high overall response rate (ORR) at 92% and a high complete response (CR) rate at 76% in patients with iNHL at a median follow-up of 17.5"
YouTube Link 2021-02-02T13:19Z 16.8K followers, [--] engagements

"Perspectives on allogeneic NK cell-based immunotherapy Monika Holubov PhD Charles University Faculty of Medicine Pilsen Czech Republic talks on strategies to improve allogeneic natural killer (NK) cell-based immunotherapy for the treatment of hematological malignancies. Indeed whilst allogeneic NK cells are currently being evaluated in many clinical trials intents to use them to target tumors have not been successful. It is necessary to improve the culture conditions of healthy donor NK cells to enhance the expression of activation molecules and improve NK cell persistence. According to Dr"
YouTube Link 2022-04-05T14:24Z 16.8K followers, [---] engagements

"Practical advice for the management of patients with CML who are pregnant or wish to conceive Elisabetta Abruzzese MD PhD S. Eugenio University Hospital Rome Italy summarizes her talk on fertility and pregnancy in patients with chronic myeloid leukemia (CML). Current data suggest that cessation of therapy is not necessary for male patients who wish to conceive with their female partners. However as tyrosine kinase inhibitor (TKI) therapy is teratogenic and embryotoxic great care must be taken to stop TKIs in female patients during the period of organogenesis. Imatinib and nilotinib can be"
YouTube Link 2024-09-06T13:56Z 16.8K followers, [---] engagements

"VMP Dara versus Rd Dara in transplant-ineligible patients with myeloma: a Phase IV trial Mattia DAgostino MD University of Turin Turin Italy discusses the results of the randomized Phase IV Real MM trial (NCT03829371) which compared bortezomib-melphalan-prednisone (VMP) +/- daratumumab (Dara) to lenalidomide-dexamethasone (Rd) +/- Dara in transplant-ineligible patients with multiple myeloma treated in the real-world setting. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected"
YouTube Link 2026-01-26T12:12Z 17K followers, [--] engagements

"Advances in menin inhibition for AML: experience with revumenib and recent approval of ziftomenib David Sallman MD Moffitt Cancer Center Tampa FL discusses advances in menin inhibition for acute myeloid leukemia (AML) highlighting the real-world experience with revumenib and recent approval of ziftomenib. Dr Sallman emphasizes the promising data on combining menin inhibition with other therapies and its potential for measurable residual disease eradication. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical"
YouTube Link 2025-12-08T08:01Z 16.6K followers, [--] engagements

"The role of megakaryocyte impairment in ITP Immune thrombocytopenia (ITP) is an autoimmune reaction against platelets driving their breakdown and resulting in excess bleeding. Paolo Gresele MD PhD University of Perugia Perugia Italy discusses the impairment of megakaryocytes and their role in ITP. Recent studies have begun to elucidate the mechanisms which cause a reduction in platelet production from these cells. Prof. Gresele explains how autoantibodies in ITP prevent megakaryocyte maturation migration and proplatelet formation and highlights the importance of this research in the"
YouTube Link 2023-07-26T15:26Z 16.5K followers, [---] engagements

"The myeloma trial portfolio in the UK: data in high-risk disease and smoldering myeloma In this video Sarah Gooding MD PhD Weatherall Institute of Molecular Medicine University of Oxford Oxford UK comments on the United Kingdom's strong history of investigator-led studies in multiple myeloma (MM) highlighting the country's exciting trial portfolio at different stages in the disease course. Additionally Dr Gooding encourages clinicians to leverage translational science to improve precision patient care and diagnostics. This interview took place at the 5th Oxford Myeloma Workshop in Oxford UK."
YouTube Link 2025-02-25T17:02Z 14.8K followers, [--] engagements

"Stephen Nimer: MDS highlights Stephen Nimer MD Sylvester Comprehensive Cancer Center and University of Miami Miami FL gives us his personal highlights from this years meeting. Specifically the exciting drugs being developed to treat anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020) held in Tel Aviv Israel"
YouTube Link 2020-03-16T16:02Z 16.5K followers, [---] engagements

"The efficacy of CAR T-cell therapy in Richters transformation Jennifer Woyach MD The Ohio State University Columbus OH discusses a study investigating the efficacy of CAR T-cell therapy in Richters transformation. The study revealed relatively short progression-free survival (PFS) and Dr Woyach emphasizes the need for further research to explore the potential role of early intervention with CAR T-cell therapy possibly as a bridge to transplantation. This interview took place at the [----] European Research Initiative on CLL (ERIC) Meeting in Barcelona Spain. These works are owned by Magdalen"
YouTube Link 2024-10-14T15:08Z 16.7K followers, [---] engagements

"Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS Amer Zeidan MBBS MHS Yale University and Yale Cancer Center New Haven CT discusses the correlation between treatment-emergent cytopenias and clinical response observed in the Phase III IMerge trial (NCT02598661) of imetelstat in patients with lower-risk myelodysplastic syndromes (LR-MDS). Dr Zeidan highlights that patients who experience thrombocytopenia and neutropenia early on after treatment initiation have a higher chance of achieving transfusion independence reflecting the agent's mechanism"
YouTube Link 2025-12-12T10:06Z 16.7K followers, [--] engagements

"ZUMA-7 subgroup analysis: axi-cel vs SOC in elderly patients with R/R LBCL Anna Sureda MD PhD Catalan Institute of Oncology Duran I Reynals Hospital Barcelona Spain comments on the outcomes of elderly patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) vs standard of care (SOC) from the ZUMA-7 study (NCT03391466). Dr Sureda highlights the superiority of axi-cel in this patient population in terms of efficacy tolerability as well as in terms of patient-reported outcomes. This interview took place at the European Hematology Association (EHA) Congress 2022"
YouTube Link 2022-06-20T17:03Z 16.8K followers, [--] engagements

"Bringing epcoritamab into earlier lines of therapy for DLBCL In this video Marek Trnn MD Charles University Hospital Prague Czech Republic briefly discusses the potential of bringing the bispecific antibody epcoritamab into earlier lines of treatment for diffuse large B-cell lymphoma (DLBCL) to improve patient outcomes. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved"
YouTube Link 2025-10-17T11:29Z 16.3K followers, [--] engagements

"New therapies in multiple myeloma Rafael Fonseca MD from the Mayo Clinic Scottsdale AZ talks about the new therapies in multiple myeloma such as ixazomib elotuzumab daratumumab and Isatuximab. Recorded at the American Society of Hematology (ASH) [----] Annual Meeting in Orlando FL"
YouTube Link 2016-02-10T17:36Z 16.8K followers, [--] engagements

"Prognosis and treatment in high-risk MDS Drorit Merkel MD Cancer Biology Research Center Tel Aviv University Tel Aviv Israel discusses the unmet need for novel treatments in high-risk myelodysplastic syndromes (MDS) with reference to the advantages and disadvantages of using azacitidine. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020) held in Tel Aviv Israel"
YouTube Link 2020-03-12T12:53Z 16.6K followers, [----] engagements

"Advances in the prevention and treatment of GvHD Mohamad Mohty MD PhD Saint-Antoine Hospital Paris France outlines recent advances in the field of graft-versus-host disease (GvHD). To start with the introduction of post-transplant cyclophosphamide (PTCy) has greatly improved the prevention of GvHD. Moreover while in the frontline setting both acute and chronic GvHD are still mostly treated with high-dose steroids several drugs have recently been approved for the treatment of refractory GvHD. These include ibrutinib ruxolitinib and belumosudil and together with advances in microbiota"
YouTube Link 2022-03-24T17:27Z 16.8K followers, [---] engagements

"New therapies for R/R multiple myeloma: CAR T-cells bispecifics & ongoing research Rahul Banerjee MD FACP Fred Hutchinson Cancer Center Seattle WA discusses the development of new therapies for relapsed/refractory multiple myeloma (RRMM) highlighting the promise of GPRC5D-directed CAR-T therapies and novel bispecific antibodies that may help to prevent relapse after CAR-T. Dr Banerjee notes that these emerging therapies have shown encouraging results including equal efficacy in BCMA-exposed and non-exposed patients and may offer new strategies for addressing unmet needs in RRMM. This"
YouTube Link 2025-12-03T16:30Z 16.6K followers, [--] engagements

"Key debates in MDS at ASH 2025: diagnosis pre-disease therapy & more Valeria Santini MD University of Florence Florence Italy discusses the key debates in myelodysplastic syndromes (MDS) that were discussed at ASH [----]. These include the diagnosis of MDS and the potential shift from morphology to molecular characterization as well as the use of pre-disease therapy in patients with germline predisposition to MDS. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright"
YouTube Link 2025-12-10T15:04Z 16.7K followers, [--] engagements

"Facilitating CAR T-cell manufacturing: short-term CAR T-cells and in vivo CAR delivery Christian Buchholz PhD Paul-Ehrlich-Institut Langen Germany comments on the advancements in CAR T-cell manufacturing mentioning two novel strategies being developed short-term CAR T-cells and in vivo CAR delivery. Prof. Buccholz also highlights the safety of short-term CAR T-cells which was investigated in murine models and in vitro assays. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting held in Strasbourg France. These works are owned by Magdalen Medical Publishing (MMP) and are"
YouTube Link 2025-02-13T13:58Z 14.7K followers, [--] engagements

"The diagnosis and management of MDS/MPN with neutrophilia (atypical CML) Massimo Breccia MD Sapienza University Rome Italy discusses the diagnosis and treatment of myelodysplastic and myeloproliferative neoplasms (MDS/MPN) with neutrophilia a malignancy previously known as atypical chronic myeloid leukemia (CML). The diagnosis of this disease is assisted by next-generation sequencing (NGS) and the malignancy must be accurately distinguished from chronic myelomonocytic leukemia (CMML) and chronic neutrophilic leukemia (CNL). The prognosis of patients with this rare disease remains poor and"
YouTube Link 2024-09-09T12:26Z 16.9K followers, [---] engagements

"NUTRIVENTION-5: a dietary intervention for NDMM with standard induction chemotherapy Urvi Shah MD Memorial Sloan Kettering Cancer Center New York City NY gives an update on the NUTRIVENTION-5 study (NCT07226609) which will investigate the impact of a dietary intervention on treatment response and/or quality of life for people with newly diagnosed multiple myeloma (NDMM) receiving standard induction chemotherapy with daratumumab (or isatuximab) lenalidomide bortezomib and dexamethasone (DRVd). If you're interested in getting in touch please contact: shahnutrivention@mskcc.org. This interview"
YouTube Link 2025-12-08T11:55Z 16.6K followers, [--] engagements

"Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma Krina Patel MD The University of Texas MD Anderson Cancer Center Houston TX presents the updated results from the iMMagine-1 study (NCT05396885) a Phase II registrational trial of anitocabtagene autoleucel (anito-cel) in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Patel highlights the highly encouraging safety and efficacy data observed with this CAR T-cell construct thus far including promising rates and depth of response as well as a favorable safety profile. This interview took place at the"
YouTube Link 2026-01-09T13:39Z 16.8K followers, [--] engagements

"A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma Juan Du MD Changzheng Hospital Shanghai China discusses two Phase I trials (NCT04935580 NCT05840107) evaluating the safety and efficacy of a dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as a first-line (1L) treatment for newly diagnosed multiple myeloma (MM). The two studies demonstrated encouraging results including high response rates measurable residual disease (MRD) negativity and a favorable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition"
YouTube Link 2026-01-07T11:22Z 16.8K followers, [--] engagements

"CyborD-DARA combination in first-line treatment for multiple myeloma Michael ODwyer MD PhD from the National University of Ireland Galway Ireland discusses the advantages of bringing daratumumab in the first-line setting as the CyborD-DARA combination ( cyclophosphamide bortezomib and dexamethasone with daratumumab) for the treatment of multiple myeloma. Here Prof. O Dwyer highlights that cyclophosphamide can activate macrophages and therefore enhance antibody-dependent cellular phagocytosis. This interview took place at the Controversies in Multiple Myeloma (COMy) [----] World Congress in"
YouTube Link 2019-06-14T15:23Z 16.8K followers, [----] engagements

"Long-term efficacy of zanubrutinib in patients with R/R CLL enrolled in the ALPINE trial Constantine Tam MBBS (Hons) MD FRACP FRCPA Alfred Hospital and Monash University Melbourne Australia discusses the long-term outcomes of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receiving zanubrutinib in the Phase III ALPINE study (NCT03734016) and the subsequent long-term extension (NCT04170283). Prof. Tam notes that the long-term follow-up data confirm the durable efficacy and sustained progression-free survival (PFS) benefit of zanubrutinib including in patients with"
YouTube Link 2025-12-07T04:01Z 16.6K followers, [--] engagements

"Take-home message on CAR T-cell therapy for lymphoma from ASH [----] The efficacy results of the major CAR T-cells in development have been very positive. In this interview Jeremy Abramson MD of Massachusetts General Hospital Boston MA emphasizes the take-home message of what we have learned from the latest CAR T-cell studies. Dr Abramson also discusses the differences in the toxicity profiles of the main CAR T-cell therapies and what may cause this in addition to the reversibility of the toxicities. This video was recorded at the American Society of Hematology (ASH) [----] Annual Meeting and"
YouTube Link 2018-01-04T17:41Z 16.8K followers, [---] engagements

"Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma Ola Landgren MD PhD Sylvester Comprehensive Cancer Center & University of Miami Miami FL discusses the role of daratumumab in smoldering multiple myeloma (MM) and introduces the REVIVE study (NCT06100237) a Phase II trial investigating the combination of teclistamab and daratumumab for high-risk smoldering myeloma. Prof. Landgren highlights the potential for this combination to achieve deep responses and high rates of measurable residual disease (MRD) negativity. This interview took place at the 67th"
YouTube Link 2026-01-06T09:09Z 16.8K followers, [--] engagements

"Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior Nicholas Short MD The University of Texas MD Anderson Cancer Center Houston TX discusses the findings of a comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) highlighting that NGS-based MRD is more sensitive and potentially more specific for the lymphoblast clone. However Dr Short notes that both methods should be used when considering discontinuation"
YouTube Link 2025-12-07T19:01Z 16.6K followers, [--] engagements

"Race-agnostic AI models maintain accuracy in predicting M-protein levels in multiple myeloma In this video Ehsan Malek MD Roswell Park Comprehensive Cancer Center Buffalo NY discusses the potential of using artificial intelligence (AI) models in multiple myeloma (MM) to predict serum M-protein levels and highlights that the addition of race data to these machine learning models does not affect their accuracy and predictive power. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are"
YouTube Link 2026-01-14T10:29Z 16.9K followers, [--] engagements

"Harnessing NK cells for cancer immunotherapies Juliane Mietz University Of Zurich Zurich Switzerland discusses her research on the development of natural killer (NK) cell-based immunotherapies for the treatment of cancer including studies comparing chimeric antigen receptor (CAR) T-cells with CAR-NK cells. Both were initially optimized to include a CD28 or 4-1BB costimulatory domain to accurately assess efficacy as well as reflect their potential clinical use where the domains are currently used in axicabtagene ciloleucel and tisagenlecleucel. She additionally describes efforts to further"
YouTube Link 2022-04-12T11:35Z 16.8K followers, [---] engagements

"Lenalidomide maintenance therapy in patients with multiple myeloma and high-risk cytogenetics The use of lenalidomide as maintenance therapy after autologous stem cell transplantation (autoSCT) in patients with high-risk multiple myeloma is currently debated in the clinical field. In this video Maria-Victoria Mateos MD PhD University of Salamanca Salamanca Spain comments on the potential benefits of lenalidomide maintenance in this patient population based on results from a post-hoc analysis conducted by the Myeloma UK group. Dr Mateos also discusses the importance of exploring novel"
YouTube Link 2023-05-17T15:08Z 16.8K followers, [---] engagements

"Translocation 4;14 in multiple myeloma: is it truly a marker of high-risk disease Mattia D'Agostino MD University of Turin Turin Italy discusses the variability in risk among patients with multiple myeloma with translocation 4;14. Dr D'Agostino highlights that identifying which patients are high-risk can be achieved by looking at combinations with other high-risk cytogenetic abnormalities or by examining the site of disruption. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025) held in Charleston SC. These works are owned by Magdalen"
YouTube Link 2025-11-03T11:01Z 16.4K followers, [--] engagements

"Using TALEN gene editing to improve the efficacy of T-cell therapies In this video Roman Galetto PhD Cellectis Paris France shares some insights into how TALEN gene editing can be used for different knockouts to minimize the risk of graft-versus-host disease (GvHD) as well as improve the overall efficacy and applicability of T-cell therapies used in the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) [----] held in Paris France"
YouTube Link 2022-05-17T14:45Z 16.9K followers, [---] engagements

"Evolving strategies in MPNs: big data analysis wearable devices & targeted therapies Claire Harrison MD FRCP FRCPath Guy's and St Thomas' NHS Foundation Trust London UK comments on the most promising innovations and evolving strategies in the management of myeloproliferative neoplasms (MPNs). Prof. Harrison highlights advances in big data analysis wearable devices and targeted therapies. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and"
YouTube Link 2025-07-16T10:27Z 16.9K followers, [--] engagements

"The potential role of thalidomide in the treatment of thalassemia Shruti Kakkar MD Christian Medical College & Hospital Ludhiana India discusses the potential role of thalidomide in the treatment of thalassemia highlighting its potential as an alternative for patients in low- to middle-income countries with limited access to other therapies. Dr Kakkar notes that thalidomide may be of value in situations where transfusion or effective iron chelation is not feasible. This interview took place virtually. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright"
YouTube Link 2025-11-06T13:06Z 16.5K followers, [--] engagements

"A practical approach to the classification of MDS In this video Rashmi Kanagal-Shamanna MD The University of Texas MD Anderson Cancer Center Houston TX gives an overview of current approaches to the classification of myelodysplastic syndromes (MDS) and how these may be improved. Dr Kanagal-Shamanna first highlights the importance of identifying genomic aberrations in patients with MDS and then comments on the importance of using novel technologies and combining multiple techniques to better diagnose disease and enable precision medicine.This interview took place at the Tenth Annual Meeting of"
YouTube Link 2022-11-01T11:26Z 16.6K followers, [---] engagements

"TRIMM-2 update: talquetamab + daratumumab in R/R multiple myeloma Paula Rodriguez Otero MD PhD University Clinic of Navarra Pamplona Spain comments on the updated follow-up results of the TRIMM-2 study (NCT04108195) investigating talquetamab and daratumumab in patients with relapsed/refractory (R/R) multiple myeloma. The study included heavily pretreated patients including many that had received prior BCMA-directed therapy. The study's results indicated a high response rate (RR) a high proportion of patients achieving a very good partial response (VGPR) or better and promising"
YouTube Link 2023-07-12T08:53Z 16.8K followers, [---] engagements

"hTERT reduction by imetelstat correlates with clinical activity in MDS Imetelstat is a first-in-class competitive inhibitor of telomerase enzymatic activity shown in the Phase II IMerge study (NCT02598661) to achieve durable transfusion independence in patents with lower-risk myelodysplastic syndromes (MDS) relapsed/refractory to erythropoiesis stimulating agents. Valeria Santini MD University of Florence Florence Italy shares the findings of an investigation into the on-target activity of imetelstat and the clinical benefits demonstrated in the trial. An optimal pharmacodynamic (PD) effect"
YouTube Link 2022-01-28T12:34Z 16.8K followers, [---] engagements

"bb21217: next gen anti-BCMA CAR-T for R/R MM Jesus Berdeja MD Director of Myeloma Research Sarah Cannon Research Institute Nashville TN gives an update on the results from an ongoing phase I clinical study (CRB-402; NCT03274219) of bb21217 a next-generation anti-BCMA CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) [----] Annual Meeting and Exposition in Orlando FL"
YouTube Link 2020-01-24T15:45Z 16.8K followers, [--] engagements

"MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101 Marc Hoffman MD University of Kansas Medical Center Kansas City KS shares initial results from the Phase I/Ib BGB-11417-101 study (NCT04277637) of sonrotoclax plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Hoffman highlights that the study used measurable residual disease (MRD) status to guide treatment discontinuation with follow-up ongoing to assess progression-free survival rates. This interview took place at the 67th ASH Annual Meeting and Exposition"
YouTube Link 2025-12-16T14:37Z 16.7K followers, [--] engagements

"Ruxolitinib and ibrutinib: the future for GvHD treatment At present the standard frontline therapy of steroids for graft versus host disease (GvHD) has shown to be ineffective for many patients. Now speaking from the [----] Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver CO Katie Gatwood PharmD BCOP of Vanderbilt University Medical Center Nashville TN provides an interesting update on the use of ibrutinib or ruxolitinib for the treatment GvHD. Dr Gatwood gives an insight on current studies that are investigating the use of ruxolitinib for acute and chronic GvHD"
YouTube Link 2018-04-04T15:50Z 16.8K followers, [----] engagements

"Current and emerging treatment options for anemia in MF Francesco Passamonti MD University of Insubria Varese Italy gives an overview of treatment options available for patients with myelofibrosis (MF) and anemia including momelotinib pacritinib and combinations with ruxolitinib. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved"
YouTube Link 2023-10-10T10:28Z 16.8K followers, [--] engagements

"CAR T-celldriven induction of iNOS in TAMs promotes CAR T-cell resistance in B-cell lymphoma Marco Davila MD PhD Roswell Park Comprehensive Cancer Center Buffalo NY discusses research identifying tumor-associated macrophages (TAMs) as a key driver of resistance to CD19 CAR T-cell therapy in lymphoma. Preclinical models demonstrated TAMs can impair or kill CAR T-cells through metabolic and proteomic mechanisms highlighting inducible nitric oxide synthase (iNOS) as a potential therapeutic target to improve durable responses. This interview took place at the 67th ASH Annual Meeting and"
YouTube Link 2026-01-21T11:15Z 16.9K followers, [--] engagements

"Updates in newly diagnosed and R/R AML Amir Fathi MD MPH Massachusetts General Hospital Boston MA shares some of the key updates in acute myeloid leukemia (AML) from the ASH [----] meeting. In the newly diagnosed AML space Dr Fathi comments on the AGILE (NCT03173248) and LACEWING (NCT02752035) trials. Several novel agents under investigation for relapsed/refractory (R/R) disease also sparked interest including SNDX-5613 a potent selective protein-protein interaction inhibitor of menin and HM43239 a novel FLT3 inhibitor which additionally targets SYK. Finally Dr Fathi highlights the Phase III"
YouTube Link 2022-01-21T09:20Z 16.4K followers, [---] engagements

"Emicizumab for severe von Willebrand disease: the EmiVWD study In this interview Jonathan Roberts MD The Bleeding & Clotting Disorders Institute Peoria IL introduces the EmiVWD trial (NCT05500807) a pilot multicenter prospective open-label study evaluating emicizumab prophylaxis in severe von Willebrand disease (VWD). The trial also allows for enrollment of patients with concomitant hemophilia A and VWD. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and"
YouTube Link 2025-12-15T11:50Z 16.7K followers, [--] engagements

"Identifying early signs of amyloidosis: increasing awareness education & improving diagnoses Joselle Cook MBBS Mayo Clinic Rochester MN comments on the value of identifying early signs and symptoms of systemic light chain (AL) amyloidosis a condition associated with significant morbidity and mortality. Dr Cook highlights the need for clinicians to be aware of the vague but distinct patterns of fatigue weight loss and cardiac symptoms which can trigger suspicion of systemic amyloidosis. She proposes the development of better infographics and educational material as well as the integration of"
YouTube Link 2025-01-14T15:52Z 16.7K followers, [----] engagements

"Clinical guidance for the use of bispecific antibodies in NHL In this video Jason Westin MD FACP The University of Texas MD Anderson Cancer Center Houston TX comments on the unique toxicity profile associated with bispecific antibodies and provides guidance for physicians treating patients with non-Hodgkin lymphoma (NHL) using this class of agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the"
YouTube Link 2023-10-10T10:37Z 16.7K followers, [---] engagements

"AlloSCT in older fit patients with AML: understanding predictors of post-transplant toxicity Charles Craddock CBE FRCP(UK) FRCPath DPhil FMedSci University of Birmingham Birmingham UK discusses the increasing importance of allogeneic stem cell transplantation (alloSCT) as a curative modality in older fit patients with acute myeloid leukemia (AML). Prof. Craddock emphasizes that age is no longer the primary consideration for alloSCT and that the unmet need is to understand the predictors of post-transplant toxicity. This interview took place at the 67th ASH Annual Meeting and Exposition held"
YouTube Link 2025-12-06T10:06Z 16.6K followers, [--] engagements

"The survival impact of increasing access to CAR T-cell therapy for R/R DLBCL: an analysis in the US Frederick Locke MD Moffitt Cancer Center Tampa FL discusses an analysis exploring the survival impact of not receiving CAR T-cell therapy when eligible in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US). Dr Locke notes that the current number of patients receiving CAR T-cell therapy is inadequate and that increasing access to this treatment could have a big impact. This interview took place at the 67th ASH Annual Meeting and Exposition"
YouTube Link 2025-12-09T12:10Z 16.7K followers, [--] engagements

"Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) Jane Churpek MD from the University of Chicago Chicago IL describes the importance of assessing the germline composition in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) [----] in Munich Germany. She explains that the germline is typically used as a comparison to identify acquired mutations however she argues that we should focus on the germline to determine the proportion of patients with a germline predisposition to leukemia."
YouTube Link 2017-03-07T15:21Z 16.5K followers, [---] engagements

"Pociredir in sickle cell disease: mechanism of action and Phase Ib trial design Sheinei Alan MD PhD Inova Schar Cancer Institute Fairfax VA discusses the mechanism of action of pociredir a novel oral fetal hemoglobin (HbF) inducer in development for the treatment of sickle cell disease (SCD). Dr Alan then outlines the trial design and endpoints of the Phase Ib study (NCT05169580) investigating pociredir in SCD. This interview took place virtually. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are"
YouTube Link 2025-11-04T12:04Z 16.4K followers, [--] engagements

"MANIFEST: ruxolitinib plus pelabresib for JAK-inhibitor nave myelofibrosis Marina Kremyanskaya MD PhD Icahn School of Medicine at Mount Sinai New York NY talks on the findings of a subgroup analysis of Arm [--] of the Phase II MANIFEST study (NCT02158858) investigating pelabresib in combination with ruxolitinib for patients with myelofibrosis who are JAK inhibitor-nave. Pelabresib is a first-in-class oral small-molecule BET inhibitor. Dr Kremyanskaya reports that at [--] weeks 67% of patients achieve a 35% reduction in spleen volume with a median reduction of 50%. Pelabresib was generally"
YouTube Link 2021-06-16T13:40Z 16.8K followers, [---] engagements

"Insights into the main subtypes of PTCL In this video Francisco Vega MD PhD The University of Texas MD Anderson Cancer Center Houston TX briefly highlights the importance of gene expression profiling studies in peripheral T-cell lymphoma (PTCL). Prof. Vega shares some insights into the biology underlying the two major subtypes of PTCL as well as the importance of better understanding these. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by"
YouTube Link 2022-11-18T10:21Z 16.9K followers, [--] engagements

"Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL Sattva Neelapu MD University of Texas MD Anderson Cancer Center Houston TX outlines the design and updated findings of the Phase II ZUMA-5 study evaluating axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (NHL) (NCT03105336). This study included patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL) who had received at least two lines of prior therapy. The study reported overall response rates (ORR) of 94% and 83% and complete response"
YouTube Link 2022-01-25T10:21Z 16.8K followers, [--] engagements

"Assessing PFS and alternative endpoints for advanced cancer clinical trials Jurjen Versluis MD PhD Erasmus MC Cancer Institute Rotterdam Netherlands discusses progression-free survival (PFS) as an endpoint in advanced cancer clinical trials and other endpoints that may be suitable alternatives. Dr Verluis emphasizes the importance of long-term follow-up to assess overall survival (OS) benefits as well as the validation of alternative endpoints such as measurable residual disease (MRD). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow Scotland. These works are owned"
YouTube Link 2024-04-24T16:05Z 16.6K followers, [---] engagements

"Pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia Prithviraj Bose MD The University of Texas MD Anderson Cancer Houston TX shares the findings of a retrospective head-to-head comparison of pacritinib versus ruxolitinib in ruxolitinib-nave patients with myelofibrosis and moderate-severe thrombocytopenia. Study participants were enrolled in the randomized Phase [--] PERSIST-2 study (NCT02055781) which compared the efficacy of pacritinib to best available therapy - ruxolitinib in 45% of cases- on spleen volume reduction (SVR) and modified total symptom score (TSS)"
YouTube Link 2022-01-05T17:52Z 16.8K followers, [---] engagements

"An overview of promising therapeutic approaches being explored in newly diagnosed and R/R myeloma In this interview Claudio Cerchione MD PhD Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy provides an overview of recent advances in the field of multiple myeloma (MM) and discusses promising therapeutic approaches being explored in both the newly diagnosed and relapsed/refractory (R/R) setting to improve patient outcomes and provide a potential cure. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL. These"
YouTube Link 2026-01-20T12:51Z 16.9K followers, [--] engagements

"Dara-VRd in multiple myeloma with high-risk cytogenetics: insights from the PERSEUS trial Meletios Dimopoulos MD Kapodistrian University of Athens School of Medicine Athens Greece discusses the PERSEUS trial (NCT03710603) which established daratumumab bortezomib lenalidomide and dexamethasone (Dara-VRd) as a new standard of care (SoC) for transplant-eligible multiple myeloma (MM). While patients with high-risk cytogenetics showed improved outcomes with this regimen an unmet treatment need remains for this group. This interview took place at the 29th Congress of the European Hematology"
YouTube Link 2024-06-20T07:23Z 16.8K followers, [---] engagements

"Dual-targeting of Slamf-7 and CD38 with elotuzumab and isatuximab in multiple myeloma Luciano Costa MD PhD UAB School of Medicine Birmingham AL presents findings from a Phase II trial (NCT04835129) exploring the dual-targeting of SLAMF7 and CD38 using monoclonal antibodies in multiple myeloma (MM) treatment. The combination of isatuximab and elotuzumab along with pomalidomide and dexamethasone demonstrated good tolerability and high response rates even in patients with prior exposure to anti-CD38 antibodies. This interview took place at the 65th ASH Annual Meeting and Exposition held in San"
YouTube Link 2024-02-20T11:21Z 16.7K followers, [---] engagements

"CAR T-cell therapy in lenalidomide-refractory multiple myeloma In this video Hermann Einsele MD FRCP University of Wrzburg Wrzburg Germany briefly discusses the possibility of using CAR T-cell therapy in lenalidomide-refractory patients with multiple myeloma (MM). As more patients become triple-class exposed and lenalidomide-refractory data from the CARTITUDE-4 trial (NCT04181827) suggests that this patient population may benefit significantly from CAR-T therapy. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia Spain. These works are owned by Magdalen"
YouTube Link 2024-02-21T16:21Z 16.8K followers, [--] engagements

"MGIP as a stable premalignant entity preceding hematologic malignancy Irene Ghobrial MD Dana-Farber Cancer Institute Boston MA discusses the concept of monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy. She highlights that MGIP is a clonal condition with the same B-cell receptor sequences as monoclonal gammopathy of undetermined significance (MGUS) and myeloma and that over 80% of MGIP cases progress to MGUS or smoldering myeloma. This interview took place at the 67th ASH Annual Meeting and Exposition held in Orlando FL."
YouTube Link 2025-12-08T16:11Z 16.6K followers, [--] engagements

"The future of CML treatment and cures Giuseppe Saglio MD of the University of Turin Turin Italy discusses the future of chronic myeloid leukemia (CML) treatment. According to Prof Saglio for a specific group of patients the future will be a real cure. This may only be achievable in 10-15% of patients even with imatinib treatment. With 2nd generation tyrosine kinase inhibitors (TKI) this may be improved to 30-35%. There are however patients that cannot receive TKI treatment. Prof Saglio discusses the need to find the best combination therapy which may be beneficial for all patients. Recorded"
YouTube Link 2016-07-14T09:10Z 16.6K followers, [----] engagements

"RESPONSE-2 5-year follow-up update: ruxolitinib vs BAT in polycythemia vera without splenomegaly Francesco Passamonti MD University of Insubria Varese Italy gives an update on the RESPONSE-2 trial comparing ruxolitinib vs best available therapy (BAT) in patients with polycythemia vera (PV) without splenomegaly (NCT02038036). After a five-year follow-up the study reported durable hematocrit control as well as a significant decrease in the number of phlebotomies. In addition there were no new safety signals. These data support the use of ruxolitinib as a second-line therapy in this patient"
YouTube Link 2022-06-28T12:17Z 16.8K followers, [---] engagements

"Targeting apoptosis - developing drugs to inhibit Bcl-2 and Mcl-1 Andreas Strasser MSc PhD of the The Walter and Eliza Hall Institute Parkville Australia talks about the development of new drugs for the inhibiton of various proteins that several cancers are dependent on. Prof. Strasser explains that there is one drug that has already been approved and is being used in certain countries for the treatment of chronic lymphocytic leukemia (CLL). This cancer happens to be highly dependent on a protein called Bcl-2 which is a family of proteins responsible for regulating apoptosis. This drug only"
YouTube Link 2017-01-19T12:04Z 16.9K followers, [----] engagements

"One big question with Naval Daver: what AML advance could transform frontline care in three years In this special 'One Big Question' segment Naval Daver MD The University of Texas MD Anderson Cancer Center Houston TX shares his perspectives on the most important development poised to transform frontline treatment in acute myeloid leukemia (AML) over the next three years emphasizing the impact of menin inhibitors. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025) held in Washington DC. These works are owned by Magdalen Medical Publishing (MMP) and are"
YouTube Link 2025-10-29T09:28Z 16.4K followers, [--] engagements

"CAR-T in DLBCL: 4-year follow-up data from ZUMA-1 Anna Sureda MD PhD Catalan Institute of Oncology Barcelona Spain discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore there were no additional toxicity signs reported in this long-term"
YouTube Link 2021-02-16T10:51Z 16.8K followers, [---] engagements

"The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib It is an exciting time in the field of graft versus host disease (GvHD) research as new drugs for the treatment of this disease in post-transplant patients have been FDA approved or received breakthrough therapy designation. Such drugs include ruxolitinib and ibrutinib and although these drugs have shown to be effective in treating patients with GvHD there are still challenges that pharmacists must be aware of. Here Katie Gatwood PharmD BCOP of Vanderbilt University Medical Center Nashville TN"
YouTube Link 2018-04-04T15:50Z 16.8K followers, [---] engagements

"The role and future of BCL2 inhibitors in HR-MDS In this video Sangeetha Venugopal MD MS Sylvester Comprehensive Cancer Center University of Miami Miami FL discusses the current role of BCL2 inhibitors in high-risk myelodysplastic syndromes (HR-MDS). She notes that she believes venetoclax still has a role in some patients despite the negative results of the Phase III VERONA trial (NCT04401748) and briefly mentions the GLORA-4 trial (NCT06641414) a Phase III study evaluating lisaftoclax plus the hypomethylating agent (HMA) azacitidine for first-line treatment of newly diagnosed HR-MDS. This"
YouTube Link 2026-01-23T13:53Z 16.9K followers, [--] engagements

"The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T In this video Hamza Hashmi MD Memorial Sloan Kettering Cancer Center New York NY discusses the association between functionally high-risk disease and inferior outcomes after CAR T-cell therapy for relapsed/refractory (R/R) multiple myeloma (MM) highlighting that while CAR T-cell therapy can overcome the negative prognostic impact of functionally high-risk disease when given in earlier lines of treatment it may not do so as a late-line therapy. As a result of this Dr Hashmi recommends that"
YouTube Link 2026-01-12T11:15Z 16.8K followers, [--] engagements

"Managing cardiotoxicity associated with the use of ibrutinib Nirav Shah MD Medical College of Wisconsin Milwaukee WI talks on ibrutinib-associated cardiotoxicity highlighting management strategies and the potential of switching to a second-generation BTK inhibitor. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved"
YouTube Link 2023-01-24T12:41Z 16.8K followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing